Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol as a Potential Treatment for Glioma

Insys Therapeutics, Inc., a specialty pharmaceutical company that is developing and commercializing innovative drugs and novel drug delivery systems, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to its pharmaceutical cannabidiol (CBD) for the treatment of glioma, which comprises approximately eighty percent of all malignant brain tumors. The ODD includes pontine glioma (PG), a devastating form of primary brainstem glioma.Continue reading

Curbing Childhood Cancer with Cord Blood Stem Cells

September is designated as National Childhood Cancer Awareness Month. The federal health observance provides an opportunity to heighten awareness of the formidable public health challenges presented by childhood cancer. According to the National Cancer Institute, cancer is the leading cause of death by disease in children and adolescents ages 1 to 19 years old in the United States.Continue reading